摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基吲唑 | 41748-71-4

中文名称
4-氨基吲唑
中文别名
4-氨基-1H-吲唑;1H-吲唑-4-胺
英文名称
4-aminoindazole
英文别名
4-amino-1H-indazole;1H-indazol-4-amine
4-氨基吲唑化学式
CAS
41748-71-4
化学式
C7H7N3
mdl
MFCD03305710
分子量
133.153
InChiKey
MDELYEBAXHZXLZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    148-150°C
  • 沸点:
    376.6±15.0 °C(Predicted)
  • 密度:
    1.367±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.7
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 安全说明:
    S26,S36/37/39
  • 危险品运输编号:
    UN 3259
  • 海关编码:
    2933990090
  • 危险品标志:
    Xn
  • 危险类别码:
    R34
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件:2-8°C,避光,惰性气体保护。

SDS

SDS:46c73845ecd9aeefa1869f15324f7e92
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1H-Indazol-4-amine
Synonyms: 4-Aminoindazole

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1H-Indazol-4-amine
CAS number: 41748-71-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H7N3
Molecular weight: 133.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-氨基吲唑硫酸 作用下, 生成 4-氰基-1H-吲唑
    参考文献:
    名称:
    v. Auwers; Schwegler, Chemische Berichte, 1920, vol. 53, p. 1213,1216, 1227
    摘要:
    DOI:
  • 作为产物:
    描述:
    4-硝基吲唑铁粉氯化铵 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以81%的产率得到4-氨基吲唑
    参考文献:
    名称:
    A regioselective C7 bromination and C7 palladium-catalyzed Suzuki–Miyaura cross-coupling arylation of 4-substituted NH-free indazoles
    摘要:
    描述了对4-取代的1H-吲唑进行区域选择性的C7-溴化,随后进行钯催化的Suzuki-Miyaura反应与硼酸。
    DOI:
    10.1039/d0ra08598g
点击查看最新优质反应信息

文献信息

  • 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
    申请人:Dunn Robert
    公开号:US20080318941A1
    公开(公告)日:2008-12-25
    The present disclosure provides compounds having affinity for the 5-HT 6 receptor which are of the formula (I): wherein R 1 , R 2 , R 5 , R 6 , B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本公开提供了具有亲和力的化合物,其对5-HT 6 受体具有亲和力,其化学式为(I): 其中R1、R2、R5、R6、B、D、E、G、Q、x和n如本文所定义。本公开还涉及制备这种化合物的方法、含有这种化合物的组合物以及使用这些化合物的方法。
  • [EN] TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS TRICYCLIQUES INHIBITEURS DE PI3K ET PROCÉDÉS D'UTILISATION
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012082997A1
    公开(公告)日:2012-06-21
    Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
    具有抗癌活性、抗炎活性或免疫调节特性的Formula I的三环PI3K抑制剂化合物被描述。描述了使用Formula I的三环PI3K抑制剂化合物进行体外、原位和体内诊断或治疗哺乳动物细胞、生物体或相关病理条件的方法。Formula I化合物包括立体异构体、几何异构体、互变异构体和其药用可接受盐。虚线表示可选的双键,至少有一条虚线是双键。取代基如所述。
  • Discovery and preliminary structure–activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties
    作者:Shan Qian、Tao He、Wei Wang、Yanying He、Man Zhang、Lingling Yang、Guobo Li、Zhouyu Wang
    DOI:10.1016/j.bmc.2016.10.003
    日期:2016.12
    necessary for IDO1 inhibition, and the substituent groups at the both 4-position and 6-position largely affect inhibitory activity. The docking model exhibited that the effective interactions of 1H-indazoles with ferrous ion of heme and key residues of hydrophobic Pocket A and B ensured the IDO1 inhibitory activities. The study suggested that the 1H-indazole was a novel interesting scaffold for IDO
    吲哚胺2,3-双加氧酶1(IDO1)介导的色氨酸降解的犬尿氨酸途径被确定为逃避潜在有效免疫应答的肿瘤细胞中重要的免疫效应子途径。IDO1是抗癌治疗的一个有吸引力的靶标,并且IDO1抑制剂的发现在学术研究实验室和制药组织中都在紧锣密鼓地进行中。我们的研究发现1H-吲唑是一种具有重要IDO1抑制活性的新型关键药效团。合成了一系列新的1H-吲唑衍生物并确定了酶抑制活性,化合物2g表现出最高的活性,IC50值为5.3μM。1H-吲唑衍生物作为新型IDO1抑制剂的结构活性关系(SARs)分析表明1H-吲唑支架对于IDO1抑制是必需的,并且4位和6位的取代基都对抑制活性有很大影响。 。对接模型显示1H-吲唑与血红素亚铁离子以及疏水性口袋A和B的关键残基的有效相互作用确保了IDO1抑制活性。研究表明1H-吲唑是抑制IDO进一步发展的一种新颖有趣的支架。对接模型显示1H-吲唑与血红素亚铁离子以及疏水性口袋
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    申请人:——
    公开号:US20040157849A1
    公开(公告)日:2004-08-12
    Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    式(I)的化合物是新颖的VR1拮抗剂,可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
  • [DE] HETEROZYKLISCH SUBSTITUIERTE PENTANOL-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ENTZÜNDUNGSHEMMER<br/>[EN] HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE PENTANOL SUBSTITUES PAR UN HETEROCYCLE, PROCEDE DE PRODUCTION DE CES COMPOSES ET LEUR UTILISATION COMME AGENTS ANTI-INFLAMMATOIRES
    申请人:SCHERING AG
    公开号:WO2005003098A1
    公开(公告)日:2005-01-13
    Die Erfindung betrifft durch Chinazolin, Chinoxalin, Cinnolin, Indazol, Phthalazin, Naphthyridin, Benzothiazol, Dihydroindolon, Dihydroisoindolon, Benzimidazol oder Indol substituierte Pentanolderivate der allgemeinen Formel (I) ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer.
    这项发明涉及一种通式(I)中由咪唑啉、喹啉、喹啉、吲唑、邻苯二酰嗪、萘啉、苯并噻唑、二氢吲哚酮、二氢异吲哚酮、苯并咪唑或吲哚取代的戊醇衍生物,以及它们的制备方法和作为抗炎药的用途。
查看更多